Jubira F 10 Tablet is a combination lipid-lowering medication containing Fenofibrate 160 mg and Rosuvastatin 10 mg, indicated for the management of dyslipidemia and mixed hyperlipidemia. Fenofibrate, a fibric acid derivative, primarily reduces triglyceride levels and increases high-density lipoprotein cholesterol (HDL-C) by activating peroxisome proliferator-activated receptor alpha (PPARα), which enhances lipolysis and elimination of triglyceride-rich particles. Rosuvastatin, a potent HMG-CoA reductase inhibitor, lowers low-density lipoprotein cholesterol (LDL-C) by inhibiting the rate-limiting enzyme in cholesterol biosynthesis, leading to increased clearance of LDL particles. The combination therapy effectively addresses multiple lipid abnormalities, reducing cardiovascular risk in patients with persistent dyslipidemia despite monotherapy. Jubira F 10 is prescribed as an adjunct to diet and lifestyle modifications, including exercise and weight control. It is contraindicated in patients with active liver disease, severe renal impairment, or hypersensitivity to its components. Caution is advised in patients with a history of myopathy or those receiving concomitant lipid-lowering agents. Regular monitoring of liver function tests, renal parameters, and muscle enzymes is recommended during therapy. This combination offers a comprehensive approach to lipid management, improving patient adherence by reducing pill burden.